186 related articles for article (PubMed ID: 17922807)
1. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
Stakiw J; Bowman M; Hegadorn C; Pruss C; Notley C; Groot E; Lenting PJ; Rapson D; Lillicrap D; James P
J Thromb Haemost; 2008 Jan; 6(1):90-6. PubMed ID: 17922807
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
3. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
4. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
[TBL] [Abstract][Full Text] [Related]
5. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
6. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
9. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
Mannucci PM; Capoferri C; Canciani MT
Br J Haematol; 2004 Jul; 126(2):213-8. PubMed ID: 15238142
[TBL] [Abstract][Full Text] [Related]
11. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
12. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
[TBL] [Abstract][Full Text] [Related]
13. The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.
Delbrück C; Miesbach W
Acta Haematol; 2019; 142(2):71-78. PubMed ID: 31085919
[TBL] [Abstract][Full Text] [Related]
14. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.
Rayes J; Hommais A; Legendre P; Tout H; Veyradier A; Obert B; Ribba AS; Girma JP
J Thromb Haemost; 2007 Feb; 5(2):321-8. PubMed ID: 17087728
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
[TBL] [Abstract][Full Text] [Related]
17. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease.
Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
J Thromb Haemost; 2021 Jan; 19(1):96-106. PubMed ID: 32998182
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
19. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.
Bucciarelli P; Siboni SM; Stufano F; Biguzzi E; Canciani MT; Baronciani L; Pagliari MT; La Marca S; Mistretta C; Rosendaal FR; Peyvandi F
J Thromb Haemost; 2015 Feb; 13(2):228-36. PubMed ID: 25425019
[TBL] [Abstract][Full Text] [Related]
20. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
